Jin-shui Huan-xian formula to slow lung decline in IPF
Part of Lungs & breathing clinical trials.
This study tests an herbal formula (Jin-shui Huan-xian) to see if it can slow the worsening of lung function in people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with mild-to-moderate lung impairment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of IPF (idiopathic pulmonary fibrosis).
- Your lung function test shows moderate or better results (FVC at least 50% of predicted, DLCO at least 30% of predicted).
- You are between 40 and 85 years old.
- You are willing to take the study medicine and sign a consent form.
- You do not have other significant lung diseases (like COPD, lung cancer, active TB, etc.) or other serious health conditions that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with idiopathic pulmonary fibrosis (IPF) to learn how traditional Chinese medicine may help. By joining, you help researchers understand better ways to manage this lung condition.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This trial tests the long-term safety and effectiveness of an oral medication (HSK44459) in people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. If you were in the earlier study profile, this study lets you keep taking the medication to see if it continues to help over time.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This study tests whether adding a cough suppressant called dextromethorphan to the standard IPF medication nintedanib helps improve cough and lung function better than nintedanib alone. It is a 12-week treatment phase with a 1-week follow-up, designed for people with moderate IPF.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
Hear when a new Idiopathic Pulmonary Fibrosis(IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.